Hims & Hers Stock Plummets as Novo Nordisk Gains in Weight-Loss Drug Dispute
Hims & Hers Health shares cratered 25% after the telehealth provider announced it WOULD cease sales of its compounded weight-loss pill, a move triggered by legal action from Novo Nordisk. The Danish pharmaceutical giant filed a patent infringement lawsuit, alleging Hims' product copied the active ingredient in its FDA-approved Wegovy treatment.
Novo Nordisk shares climbed 4% as the legal victory strengthens its grip on the lucrative weight-loss drug market. Hims denounced the lawsuit as an attack on affordable healthcare access, vowing to continue fighting for compounded medication alternatives.
The abrupt withdrawal of Hims' competing product reduces near-term pressure on Novo Nordisk's market dominance. This development highlights the fierce intellectual property battles shaping the pharmaceutical industry's race to capitalize on the booming weight-loss treatment sector.
